Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and<i>nab</i>-Paclitaxel

Abstract

This study shows that paclitaxel disposition is subject to considerable variability depending on the formulation used. Because systemic exposure to unbound paclitaxel is likely a driving force behind tumoral uptake, these findings explain, at least in part, previous observations that the administration of nab-paclitaxel is associated with augmented antitumor efficacy compared with solvent-based paclitaxel.